[HTML][HTML] Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic …
DJH Tan, CH Ng, SY Lin, XH Pan, P Tay… - The Lancet …, 2022 - thelancet.com
Background The clinical presentation and outcomes of non-alcoholic fatty liver disease
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis
Background Supplemental oxygen is often administered liberally to acutely ill adults, but the
credibility of the evidence for this practice is unclear. We systematically reviewed the efficacy …
credibility of the evidence for this practice is unclear. We systematically reviewed the efficacy …
Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate …
glioblastoma remain poor, and new treatments are needed. Objective To investigate …
Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
Objective To clarify in patients with covid-19 the recovery rate of smell and taste, proportion
with persistent dysfunction of smell and taste, and prognostic factors associated with …
with persistent dysfunction of smell and taste, and prognostic factors associated with …
IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves
N Liu, Y Zhou, JJ Lee - BMC medical research methodology, 2021 - Springer
Background When applying secondary analysis on published survival data, it is critical to
obtain each patient's raw data, because the individual patient data (IPD) approach has been …
obtain each patient's raw data, because the individual patient data (IPD) approach has been …
Choosing effect measures and computing estimates of effect
A key early step in analysing results of studies of effectiveness is identifying the data type for
the outcome measurements. This chapter considers outcome data of five common types …
the outcome measurements. This chapter considers outcome data of five common types …
Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis
LM Spring, G Fell, A Arfe, C Sharma, R Greenup… - Clinical cancer …, 2020 - AACR
Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
NC Munshi, H Avet-Loiseau, KC Anderson… - Blood …, 2020 - ashpublications.org
The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …
Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis
Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …
Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma
PURPOSE The US Food and Drug Administration has granted regulatory approval for the
use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of …
use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of …